This is a great move toward biomarker-driven, tumor-site agnostic targeted therapies in oncology. I attended ASCO 2017 last week, where LOXO showcased data from larotrectinib in a variety of adult and pediatric indications with Trk-fusions. The waterfall plot is fairly impressive, and I'd be shocked if this drug was not the next to be approved across cancers based on biomarker status alone. A decent summary about it here: https://endpts.com/loxo-takes-center-stage-at-asco-with-its-... Company presentation here: https://www.loxooncology.com/docs/presentations/Hyman_Larotr...